Neuland Laboratories

Neuland Laboratories CROIC

The Cash Return on Invested Capital (CROIC) of Neuland Laboratories (NEULANDLAB.NS) as of Nov 11, 2026 is -2.71 %. In the previous year, Cash Return on Invested Capital (CROIC) was 6.59 % — a change of -141.04% (lower).

CROIC

-2.71 %

YoY

-141.04%

Last updated:

Cash Return on Invested Capital (CROIC) of Neuland Laboratories is 2026 -2.71 % . Cash Return on Invested Capital (CROIC) of Neuland Laboratories was 2025 6.59 % . It decreases by -141.04% lower compared to the previous year.

The Neuland Laboratories CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2019
0.73 INR
Jan 1, 2020
0.88 INR
Jan 1, 2021
8.67 INR
Jan 1, 2022
-3.45 INR
Jan 1, 2023
15.36 INR
Jan 1, 2024
8.13 INR
Jan 1, 2025
6.59 INR
Jan 1, 2026
-2.71 INR
The Neuland Laboratories CROIC history
YEARCROICYoY
-2.71 %-141.04%
6.59 %-18.87%
8.13 %-47.07%
15.36 %-545.15%
-3.45 %-139.81%
8.67 %+887.70%
0.88 %+20.20%
0.73 %-105.24%
-13.94 %+4,105.11%
-0.33 %-104.63%
7.16 %-1,172.02%
-0.67 %-106.57%
10.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Neuland Laboratories Stock analysis

What does Neuland Laboratories do? Neuland Laboratories Ltd. generates revenue through the manufacture and export of bulk pharmaceutical ingredients and intermediates for the generics industry. The company operates in a single segment focused on active pharmaceutical ingredients (APIs) and allied services, with two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, and Labetalol, which are supplied to both domestic and international markets. The firm provides end-to-end chemistry solutions for the pharmaceutical industry, covering synthesis of library compounds, NCEs, and advanced intermediates across clinical and commercial stages. The company's primary customers are pharmaceutical firms requiring APIs and intermediates for generic drugs, with a focus on global markets. Neuland Laboratories Ltd. serves as a solution provider for chemistry needs, offering services from early-stage development to commercial production. The business model emphasizes tailored manufacturing services under CMS, alongside standardized GDS products, catering to the full lifecycle of pharmaceutical development and production. Revenue streams are derived from the sale of specific APIs like Levetiracetam and Mirtazapine, as well as custom manufacturing services for complex chemical processes. The firm's dual verticals allow it to address diverse market demands, with GDS targeting cost-effective generic drug production and CMS focusing on specialized, high-value manufacturing solutions for pharmaceutical clients. Neuland Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuland Laboratories stock

Cash Return on Invested Capital (CROIC) of Neuland Laboratories is -2.71 % in 2026.

Cash Return on Invested Capital (CROIC) of Neuland Laboratories changed from 6.59 % to -2.71 %, representing a -141.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Neuland Laboratories since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Neuland Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Neuland Laboratories

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Neuland Laboratories